Skip to main content
Clinical Trials/IRCT20220529055013N1
IRCT20220529055013N1
Not Yet Recruiting
Phase 4

Efficacy of Dapagliflozin in diabetic and nondiabetic patients with Acute heart failure

Public Sector medical University0 sites160 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Not specified
Sponsor
Public Sector medical University
Enrollment
160
Status
Not Yet Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Public Sector medical University

Eligibility Criteria

Inclusion Criteria

  • 1\. Male/Female patients 30 years and above
  • 2\. Diagnosis of acute decompensated heart failure made on admission based on any two of the following signs and symptoms a)Dyspnea at rest or minimal exertion b)Peripheral edema c) Ascites d)5\-pound weight gain (rapid) e) Signs of congestion on X\-ray
  • 3\. Left ventricular Ejection fraction \= 40%
  • 4\. eGFR \= 30ml/min

Exclusion Criteria

  • Cardiogenic shock;
  • urgent hospitalization for acute heart failure primarily triggered by pulmonary embolism ,cerebrovascular accident, or acute myocardial infarction
  • Current hospitalization for acute heart failure not caused primarily by intravascular volume overload
  • Type 1 Diabetes mellitus
  • History of Diabetic ketoacidosis
  • History of hepatic impairment
  • Known allergy to SGLT 2 inhibitors
  • Women pregnant or breast feeding

Outcomes

Primary Outcomes

Not specified

Similar Trials